These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Antithrombotic therapy in atrial fibrillation: ximelagatran, an oral direct thrombin inhibitor. Halperin JL Expert Rev Cardiovasc Ther; 2004 Mar; 2(2):163-74. PubMed ID: 15151465 [TBL] [Abstract][Full Text] [Related]
7. Secondary prevention of venous thromboembolism with the oral direct thrombin inhibitor ximelagatran. Schulman S; Wåhlander K; Lundström T; Clason SB; Eriksson H; N Engl J Med; 2003 Oct; 349(18):1713-21. PubMed ID: 14585939 [TBL] [Abstract][Full Text] [Related]
8. Safety and efficacy of ximelagatran: meta-analysis of the controlled randomized trials for the prophylaxis or treatment of venous thromboembolism. Iorio A; Guercini F; Ferrante F; Nenci GG Curr Pharm Des; 2005; 11(30):3893-918. PubMed ID: 16305520 [TBL] [Abstract][Full Text] [Related]
9. Ximelagatran vs low-molecular-weight heparin and warfarin for the treatment of deep vein thrombosis: a randomized trial. Fiessinger JN; Huisman MV; Davidson BL; Bounameaux H; Francis CW; Eriksson H; Lundström T; Berkowitz SD; Nyström P; Thorsén M; Ginsberg JS; JAMA; 2005 Feb; 293(6):681-9. PubMed ID: 15701909 [TBL] [Abstract][Full Text] [Related]
11. Results of THRIVE treatent study show that ximelagatran is safe and effective against throbosis. J Support Oncol; 2004; 2(1):56. PubMed ID: 15330373 [No Abstract] [Full Text] [Related]
12. A dose-ranging study of the oral direct thrombin inhibitor, ximelagatran, and its subcutaneous form, melagatran, compared with dalteparin in the prophylaxis of thromboembolism after hip or knee replacement: METHRO I. MElagatran for THRombin inhibition in Orthopaedic surgery. Eriksson BI; Arfwidsson AC; Frison L; Eriksson UG; Bylock A; Kälebo P; Fager G; Gustafsson D Thromb Haemost; 2002 Feb; 87(2):231-7. PubMed ID: 11858482 [TBL] [Abstract][Full Text] [Related]
13. Direct thrombin inhibitor melagatran followed by oral ximelagatran in comparison with enoxaparin for prevention of venous thromboembolism after total hip or knee replacement. Eriksson BI; Agnelli G; Cohen AT; Dahl OE; Mouret P; Rosencher N; Eskilson C; Nylander I; Frison L; Ogren M; Thromb Haemost; 2003 Feb; 89(2):288-96. PubMed ID: 12574809 [TBL] [Abstract][Full Text] [Related]
14. Ximelagatran/Melagatran: a review of its use in the prevention of venous thromboembolism in orthopaedic surgery. Evans HC; Perry CM; Faulds D Drugs; 2004; 64(6):649-78. PubMed ID: 15018597 [TBL] [Abstract][Full Text] [Related]
18. The pharmacokinetics and pharmacodynamics of ximelagatran, an oral direct thrombin inhibitor, are unaffected by a single dose of alcohol. Sarich TC; Johansson S; Schützer KM; Wall U; Kessler E; Teng R; Eriksson UG J Clin Pharmacol; 2004 Apr; 44(4):388-93. PubMed ID: 15051746 [TBL] [Abstract][Full Text] [Related]
19. Ximelagatran for prevention and treatment of venous thromboembolism. Kwok L; Boucher M Issues Emerg Health Technol; 2004 Jun; (57):1-4. PubMed ID: 15214359 [TBL] [Abstract][Full Text] [Related]
20. Comparison of ximelagatran with warfarin for the prevention of venous thromboembolism after total knee replacement. Francis CW; Berkowitz SD; Comp PC; Lieberman JR; Ginsberg JS; Paiement G; Peters GR; Roth AW; McElhattan J; Colwell CW; N Engl J Med; 2003 Oct; 349(18):1703-12. PubMed ID: 14585938 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]